Treatment for glioblastoma (GBM)
Intended for US audiences only.

"I didn't think I'd be alive today. Now here I am with Optune®, still enjoying life."
— Marcia, an Optune user

See her story

In people with newly diagnosed GBM

Proven to extend survival and maintain quality of life

In a large clinical study, people who added Optune to chemotherapy* had a greater opportunity to live longer than those who used chemotherapy alone.

5-year survival rates with Optune® plus chemo vs chemo alone 5-year survival rates with Optune® plus chemo vs chemo alone

In a 5-year follow-up, people on Optune plus chemotherapy lived longer across all groups analyzed regardless of well-being, age, gender, and how much of the tumor was removed.

People in the study were also able to maintain their mental, emotional, and physical well-being longer than those on chemotherapy alone.

People on Optune plus chemotherapy experienced mental well-being 22% longer, emotional well-being 36% longer, and physical well-being 38% longer than those on chemotherapy alone.

Nearly half of people on Optune plus chemotherapy were alive at 2 years compared with 31% of people on chemotherapy alone.

Optune® 2-year survival rate plus chemo

In a large clinical study, people on Optune + chemotherapy lived longer than people on chemotherapy alone.

OVERALL SURVIVAL

Survival rate of Optune® plus chemo vs chemo alone

In the same study, Optune + chemotherapy delayed tumor growth longer than chemotherapy alone.

PROGRESSION-FREE SURVIVAL

Progression-free survival rate with chemo vs Optune® plus chemo

Optune treats where your GBM is located without increasing chemotherapy-related
side effects.

How Optune® treats glioblastoma (GBM) diagram How Optune® treats glioblastoma (GBM) diagram
References:
  1. Optune [Instructions for Use]. Novocure 2018.
  2. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA Oncology. 2017;318(23):2306-2316.
  3. Taphoorn M, Dirven L, Kanner A, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncology. doi:10.1001/jamaoncol.2017.5082. Published online February 1, 2018.
  4. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed May 30, 2018.

Find an Optune doctor

By ZIP code

Hear from Optune users and caregivers

Get a firsthand view

What is Optune approved to treat?

Optune is indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:

Recurrent GBM

If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:

What is the NovoTTF-100L System approved to treat?

The NovoTTF-100L System is a wearable, portable, FDA-approved device indicated for the treatment of adult patients, with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used together with standard chemotherapy (pemetrexed and platinum-based chemotherapy).

Who should not use Optune for GBM or the NovoTTF-100L System for MPM?

Optune for GBM and the NovoTTF-100L System for MPM are not for everyone. Talk to your doctor if you have:

Do not use Optune for GBM or the NovoTTF-100L System for MPM if you are pregnant or are planning to become pregnant. It is not known if Optune/the NovoTTF-100L System is safe or effective during pregnancy.

What should I know before using Optune for GBM or the NovoTTF-100L System for MPM?

Optune and the NovoTTF-100L System should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune and the NovoTTF-100L System.

What are the possible side effects of Optune for GBM and the NovoTTF-100L System for MPM?

The most common side effects of Optune when used together with chemotherapy for GBM (temozolomide or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.

The most common side effects when using Optune alone for GBM were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

The most common side effects of the NovoTTF-100L System when used together with chemotherapy for MPM (pemetrexed and platinum-based chemotherapy) were low blood platelet count, constipation, nausea, tiredness, chest pain, fatigue, skin irritation from device use, itchy skin, and cough.

Other potential adverse effects associated with the use of the NovoTTF-100L System include: treatment related skin irritation, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical site reaction and skin breakdown/skin ulcer.

Talk to your doctor if you have any of these side effects or questions.

Caution: Federal law restricts the NovoTTF-100L System to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.


Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Please click here to see the NovoTTF-100L IFU for complete information regarding the device's indications, contraindications, warnings, and precautions.


On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals. Patient images reflect the health status of the patients at the time each photo was taken.

What is Optune approved to treat?

Optune is indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.